Haleos Labs Subsidiary Clears US-FDA Inspection with Zero Observations
Haleos Labs Ltd 路 Others (Uncategorized) 路 18 Sept 2026, 5:22 pm
Haleos Labs Subsidiary Clears US-FDA Inspection with Zero Observations US-FDA successfully concluded an inspection at Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited, with zero Form 483 observations. The audit took place from 15th Sep'26 to 18th Sep'26 at its API manufacturing facility in Parawada, Anakapalli, Andhra Pradesh. This matches the clean outcome achieved during the facility's previous US-FDA inspection in Jan'25, reaffirming adherence to regulatory compliance and quality standards.
Original exchange filing (PDF)
More announcements from Haleos Labs Ltd
- Enclosed - Newspaper advertisement for Q2F27 (results) 路 12 Nov 2026
- Enclosed - Outcome of 99th Board meeting. 路 11 Nov 2026
- HALEOS LABS LIMITED has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 11 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 and other business matters 路 11 Nov 2026
- Haleos Labs Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended September 2026 and Other business. 路 11 Nov 2026
- Haleos Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2026 ,inter alia, to consider and approve the unaudited financial results .... 路 11 Nov 2026
- Dividend payable to shareholders who have not yet updated their KYC details is withheld and shall be released upon compliance with the KYC norms. 路 31 Oct 2026
- Enclosed 路 02 Oct 2026
